12
Treatment
Figure 3. Third-Line Treatment Options for Patients With
Stage IV NSCLC Without Driver Alterations
Patients with stage IV NSCLC,
PS 0–1
SCC or non-SCC
Driver alteration
a
negative
Received chemotherapy ±
bevacizumab and immune
checkpoint inhibitors
a
Driver alterations including EGFR, ALK, ROS-1, BRAF V600E, MET exon 14, NTRAK,
KRAS, and RET.
S
For patients with non-SCC only
Single-agent docetaxel
(If not received in first- or second-line)
S
Single-agent pemetrexed
(If not received in first- or second-line)
W
Paclitaxel + bevacizumab
(If not received in first- or second-line)
Strength of
Recommendation
W
Strong
Moderate
Weak
M
S
